nova Steady HealthCare invests in the global growth market of healthcare with a proven strategy
06.01.2015 15:11
nova fund management GmbH (nova), a fund initiator and consultancy specializing in the healthcare sector, announces the launch of the equity fund nova Steady HealthCare (nova SHC, DE000A1145J0 / A1145J). nova SHC focuses exclusively on the global healthcare market, which is experiencing particularly strong and sustainable growth: According to OECD forecasts, future growth in the market for healthcare products and services will significantly exceed that of gross domestic product (GDP) for many years to come. This supports nova fund management GmbH's assessment that the listed healthcare sector should outperform the stock market as a whole over the coming years. The low correlation with macroeconomic cycles makes this sector even more attractive. The fund, which is expected to be launched by Universal-Investment Gesellschaft mbH on January 15, pursues a risk-averse, supracyclical, and fundamental investment strategy that aims to outperform the MSCI World Health Care Index 1.
Two recognized experts, each with more than 15 years of investment experience in healthcare equities, Dr. Andreas Bischof and Oliver Kämmerer, are responsible for the investment strategy. Formerly employed by Allianz SE, Dr. Bischof achieved attractive excess returns over the years with an investment volume of over EUR 1 billion using a similarly risk-averse investment strategy. The nova SHC fund now makes Dr. Bischof's investment strategy available to a broader investor base for the first time. Mr. Kämmerer previously headed European equity research and healthcare equity research at WestLB. In these roles, his responsibilities included generating alpha for equity recommendations.
nova Managing Director and founder Dr. Bischof commented on the fund's launch: "We focus on quality companies with superior growth and high stability. Because a company's superior performance generates superior share price performance. Only a few established companies can fully convince us. Therefore, the nova SHC portfolio remains highly concentrated, with up to 30 stocks." nova Managing Director Oliver Kämmerer added: "Independent, fundamental analysis and careful selection of portfolio stocks are essential prerequisites for a successful investment strategy in the global healthcare market. Our high-conviction approach enables a highly attractive return profile."